Masimo (NASDAQ:MASI) issued an update on its FY20 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.58. The company issued revenue guidance of $1.035, compared to the consensus revenue estimate of $1.02 billion.Masimo also updated its FY 2019
Pre-Market guidance to 3.18 EPS.
Shares of Masimo stock traded up $2.53 during trading hours on Thursday, reaching $169.75. 1,651 shares of the company’s stock were exchanged, compared to its average volume of 304,037. The company has a 50 day moving average of $158.24 and a two-hundred day moving average of $152.15. Masimo has a fifty-two week low of $115.72 and a fifty-two week high of $167.87. The stock has a market cap of $8.75 billion, a P/E ratio of 55.42, a P/E/G ratio of 2.00 and a beta of 1.13.
Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $0.76 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.03. The company had revenue of $229.01 million during the quarter, compared to the consensus estimate of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.71 EPS. Equities analysts predict that Masimo will post 3.18 earnings per share for the current year.
A number of equities research analysts have recently issued reports on MASI shares. BidaskClub raised shares of Masimo from a hold rating to a buy rating in a report on Monday, December 16th. ValuEngine cut shares of Masimo from a buy rating to a hold rating in a report on Wednesday, October 2nd. Piper Sandler reaffirmed a buy rating and issued a $175.00 target price on shares of Masimo in a report on Wednesday. UBS Group upped their target price on shares of Masimo from $180.00 to $190.00 and gave the company a buy rating in a report on Wednesday. Finally, Piper Jaffray Companies reaffirmed an overweight rating and issued a $175.00 target price (up from $161.00) on shares of Masimo in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $165.07.
In other Masimo news, COO Bilal Muhsin sold 3,000 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $155.00, for a total transaction of $465,000.00. Also, EVP Thomas Samuel Mcclenahan sold 500 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $159.29, for a total transaction of $79,645.00. Following the transaction, the executive vice president now owns 5,607 shares in the company, valued at approximately $893,139.03. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,000 shares of company stock worth $8,683,715. Insiders own 11.50% of the company’s stock.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.